Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 19th Preview)
-
FDA OKs oral antibiotic Utebzi for complicated UTI
Spero Therapeutics’ oral carbapenem antibiotic tebipenem pivoxil hydrobromide, branded as Utebzi, has received US FDA approval for complicated urinary tract infections (cUTI), including pyelonephritis. The agency’s decision comes about four years after a prior complete response letter. The approval is backed by Phase III data showing noninferiority versus intravenous imipenem-cilastatin, giving the drug an oral option for a setting where clinicians often rely on IV therapy. Spero’s partner GSK previously secured global rights under a $600 million license deal signed in 2022 (excluding Japan and certain Asian markets tied to original development). Utebzi is expected to be available by the end of 2026. The move adds to momentum for oral alternatives to injectable antibiotics, particularly in hospital-adjacent care pathways where faster switching and outpatient treatment are key operational goals.
-
FDA advisory committee backs Moderna’s mRNA flu vaccine
Moderna’s mRNA influenza vaccine mRNA-1010 moved back into regulators’ favor as FDA vaccine advisers voted unanimously that benefits outweigh risks. The Vaccines and Related Biological Products Advisory Committee (VRBPAC) backed the vaccine 9-0 in adults aged 50 to 64 and again 9-0 for adults aged 65 and older. The vote sharpens the path for a regulatory decision expected Aug. 5, with Moderna seeking standard approval for the younger group and accelerated approval for older adults. The advisory committee previously confronted controversy after FDA leadership declined to even accept Moderna’s submission earlier in the development cycle. Panelists cited robust trial results and well-conducted studies, with the company positioning the mRNA platform as a faster route for season-to-season strain updates. For biotech and platform developers, the episode underscores how advisory committee momentum can accelerate renewed FDA engagement after earlier procedural standoffs.
-
FDA clears Diasorin’s point-of-care group A strep molecular test
Diasorin received US FDA clearance and a CLIA waiver for a multiplex group A streptococcus assay on its Liaison Nes point-of-care PCR instrument. The Liaison Nes Group A Strep test is designed to deliver results in about 15 minutes with less than one minute of hands-on time. Diasorin says the reagents can be stored at room temperature and that the compact, cloud-connected Nes platform supports real-time reporting in outpatient and decentralized settings. The group A strep test is the second cleared assay on the Nes platform, following a respiratory panel cleared in December for influenza A/B, RSV, and COVID-19. Angelo Rago, president of Diasorin’s Luminex subsidiary, tied the expansion to addressing high-impact infectious diseases. Diasorin also reiterated Nes revenue targets of more than $150 million in the US by 2030, previously outlined at an investor day. The clearance adds near-term breadth to the platform’s infectious disease menu, an area increasingly targeted by payers and clinicians seeking faster triage and stewardship.
-
Biogen buys RayThera to expand immunology small-molecule pipeline
Biogen agreed to acquire RayThera in a deal valued at up to $1 billion, adding a portfolio of early-stage immunology assets to the company’s pipeline. RayThera’s co-founders built a small-molecule discovery operation focused on anti-inflammatory programs, and Biogen says the lead candidate is positioned to enter Phase I in early Q3 2026. The acquisition provides an undisclosed upfront payment, with most value tied to future clinical and regulatory milestones. Biogen expects the deal to broaden its immunology footprint beyond its traditional neurology strengths. RayThera completed a $110 million Series A financing in 2025, with investors including Foresite Capital and OrbiMed Advisors. The startup disclosed limited pipeline detail publicly, but the reported target landscape includes commonly pursued immune pathways such as TNF modulation and JAK activity. For Biogen, the purchase arrives after its earlier acquisition of Apellis, signaling a sustained shift toward earlier-stage immunology risk-reduction and portfolio diversification.
-
Confo Therapeutics advances SSTR5 agonist CFTX-2034 for PBH
Confo Therapeutics presented preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist targeting life-threatening hypoglycemic episodes in post-bariatric hypoglycemia (PBH). The company framed the program as a focused approach to PBH, a condition that can drive recurrent severe events after surgery. CFTX-2034 is built using Confo’s proprietary platform and is designed to modulate pathways relevant to glucose dysregulation in post-bariatric patients. The preclinical package adds to the evidence base ahead of potential human development. While the update was specifically preclinical, it reinforces continued investor and academic interest in mechanistically differentiated drugs for PBH where existing treatments can be limited. The data could also influence how PBH endpoints and translational biomarkers are selected for first-in-human studies.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.